Paper Details

  1. Home
  2. Paper Details

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Author: ArthurD C, BergD T, BloomfieldC D, ByrdJ C, CarrollA, DaveyF R, LawrenceD, MayerR J, PatilS R, PettenatiM J, SchifferC A, TantravahiR

Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

In a study of 285 people with acute myeloid leukemia (AML), different doses of cytarabine chemotherapy were compared after remission. The study found that the effectiveness of cytarabine varied depending on the person's specific chromosome structure (cytogenetics). People with a specific type of chromosome structure (CBF) had the highest remission rates, especially those who received the highest dose of cytarabine. Those with normal chromosomes also showed improved remission rates with higher doses. In contrast, higher doses of cytarabine did not improve remission rates in those with other chromosome abnormalities. The study suggests that evaluating chromosomes before treatment can help determine the best treatment strategy for AML after remission.
Paper Details　
Original Abstract of the Article :
Advances in the treatment of acute myeloid leukemia (AML) have occurred with the introduction of new therapies including high-dose cytarabine and the identification of powerful prognostic factors such as cytogenetics that predict for long-term outcome. To date, the prognostic impact of cytarabine do...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/9751631

データ提供：米国国立医学図書館（NLM）

High-Dose Cytarabine: A Powerful Tool in the Fight Against Acute Myeloid Leukemia

Acute myeloid leukemia (AML), a relentless cancer of the blood and bone marrow, is a formidable opponent in the fight for life. The battle against AML is often fought with high-dose cytarabine, a powerful chemotherapy drug that can sometimes push the disease into remission. But like the shifting sands of the desert, the effectiveness of cytarabine can vary depending on the specific characteristics of the AML. This study, like a group of explorers mapping a vast, uncharted territory, aimed to investigate the impact of high-dose cytarabine on different cytogenetic subtypes of AML. The researchers meticulously studied 285 patients with newly diagnosed AML, categorizing them into three cytogenetic groups: core binding factor (CBF) type, normal karyotype, and other abnormalities.

The Impact of High-Dose Cytarabine: A Landscape of Hope and Challenges

This research, like a detailed map revealing the terrain of a desert, provides crucial insights into the effectiveness of high-dose cytarabine for AML. The study found that high-dose cytarabine was most effective in prolonging remission in patients with CBF type AML and normal karyotype AML, but had a limited impact on those with other cytogenetic abnormalities. The study also identified several factors, including age, leukocyte count, and the presence of Auer rods, as independent predictors of prolonged remission duration.

Navigating the Desert of AML: Finding Hope in the Shifting Sands

This research underscores the importance of understanding the specific characteristics of AML, as it can greatly influence the effectiveness of treatment. The findings suggest that high-dose cytarabine may be a powerful tool for prolonging remission in certain subgroups of AML, but it's not a universal solution. Individuals with AML should consult with a qualified oncologist to develop a personalized treatment plan that considers their specific cytogenetic subtype and overall health status.

Dr. Camel's Conclusion

This study, a testament to the relentless pursuit of knowledge in the face of challenging medical conditions, offers hope for patients with AML. It highlights the crucial role of cytogenetics in determining the most effective treatment strategies. The fight against AML is a journey through a vast and unforgiving desert, but with the right tools and understanding, we can navigate its treacherous terrain and emerge victorious.

Date :
  1. Date Completed 1998-10-01
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

9751631

DOI: Digital Object Identifier

9751631

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.